Previous work by Wang and colleagues already demonstrated the potential of 64Cu-labeled anti-human AXL antibodies to visualize AXL+ tumors and monitor the effect of anti-AXL therapies in triple negative breast cancer (TNBC)-bearing nude mice 24. This evidence concerns the gene AXL and triple-negative breast carcinoma.